-transparent.png){kind=logo}
The single-dose pharmacokinetics of cefsulodin were evaluated in 12 patients with cystic fibrosis. Each patient received 3 g of cefsulodin intravenously over 30 min. Multiple plasma and urine samples were obtained during the 6-h study period for the determination of cefsulodin. Pharmacokinetic parameters were determined by model-independent methods. Mean values for t1/2, Vss, and CLp were 1.53 h, 0.242 liters/kg, and 117.3 ml/min per 1.73 m2, respectively. Six-hour urine recovery revealed 73.2% of the administered dose with a corresponding cefsulodin urinary clearance of 75.1 ml/min. These pharmacokinetic data in patients with cystic fibrosis appear consistent with data reported for unaffected individuals.
M D Reed, and
R C Stern, and
T S Yamashita, and
I Ackers, and
C M Myers, and
J L Blumer
March 1986,
Journal of clinical pharmacology,
M D Reed, and
R C Stern, and
T S Yamashita, and
I Ackers, and
C M Myers, and
J L Blumer
November 2012,
Journal of clinical pharmacology,
M D Reed, and
R C Stern, and
T S Yamashita, and
I Ackers, and
C M Myers, and
J L Blumer
January 1984,
Antimicrobial agents and chemotherapy,
M D Reed, and
R C Stern, and
T S Yamashita, and
I Ackers, and
C M Myers, and
J L Blumer
November 2017,
Pediatric pulmonology,
M D Reed, and
R C Stern, and
T S Yamashita, and
I Ackers, and
C M Myers, and
J L Blumer
March 1997,
The Journal of antimicrobial chemotherapy,
M D Reed, and
R C Stern, and
T S Yamashita, and
I Ackers, and
C M Myers, and
J L Blumer
January 1985,
Clinical pharmacy,
M D Reed, and
R C Stern, and
T S Yamashita, and
I Ackers, and
C M Myers, and
J L Blumer
January 2001,
Chemotherapy,
M D Reed, and
R C Stern, and
T S Yamashita, and
I Ackers, and
C M Myers, and
J L Blumer
January 1986,
Infection,
M D Reed, and
R C Stern, and
T S Yamashita, and
I Ackers, and
C M Myers, and
J L Blumer
May 1984,
Antimicrobial agents and chemotherapy,
M D Reed, and
R C Stern, and
T S Yamashita, and
I Ackers, and
C M Myers, and
J L Blumer
January 1984,
Developmental pharmacology and therapeutics,
